Dihydroergotamine Mesylate Injection (DHE 45®)

Total Page:16

File Type:pdf, Size:1020Kb

Dihydroergotamine Mesylate Injection (DHE 45®) Place of Service Dihydroergotamine mesylate injection Office Administration (D.H.E. 45®) Home Infusion Administration Outpatient Facility Administration Infusion Center Administration Self-Administration– May be covered under the pharmacy benefit HCPCS: J1110 per 1 mg Conditions listed in policy (see criteria for details) • Cluster headaches • Migraine headaches AHFS therapeutic class: Antimigraine agent; Ergot Derivative Mechanism of action: Dihydroergotamine is a semisynthetic ergot alkaloid that is structurally and pharmacologically related to ergotamine. (1) Special Instructions and Pertinent Information If member has a Prescription Benefit, please refer cases to Pharmacy Services for prior authorization. If covered under the Medical Benefit, please submit clinical information for prior authorization review via fax. Please include medical rationale why medication cannot be home self- administered. (2) Prior Authorization/Medical Review is required for the following condition(s) All requests for D.H.E. 45® (dihydroergotamine mesylate injection) must be sent for clinical review and receive authorization prior to drug administration or claim payment. Cluster headaches 1. Recommended by a neurologist or a headache specialist, AND 2. Patient is currently on a prophylactic medication from the following list: prednisone, dexamethasone, verapamil, lithium or topiramate, OR contraindication to all agents above recognized as being efficacious for cluster headache prophylaxis, AND 3. Inadequate response, intolerable side effect, or contraindication to sumatriptan and zolmitriptan, AND 4. Number of injections requested per month does not exceed the amount needed to treat the number of headache days experienced per month, AND 5. Not taking D.H.E injection along with any triptan, or an ergot-type drug Covered Doses Up to 3 mg per 24 hours, and up to 6 mg/week, given IM or SQ Coverage Period Cover for 3 months ICD-10: G44.001, G44.009 Dihydroergotamine mesylate injection (D.H.E. 45®) Effective: 05/06/2020 Page 1 of 4 Migraine headaches for patients LESS than or equal to 8 headaches days per month 1. Treatment failure or intolerable side effect with at least 2 different triptans, AND 2. The total number of injections requested per month does not exceed the amount needed to treat the number of headache days experienced per month, AND 3. Not taking D.H.E injection along with any triptan, or an ergot-type drug Covered Doses Up to 3 mg per 24 hours, and up to 6 mg/week, given IM or SQ Coverage Period Cover indefinitely ICD-10: G43.001- G43.819, G43.A01-G43.D19 Migraine headaches for patients GREATER than 8 headaches days per month 1. Patient is currently being followed by a neurologist or at a headache clinic, AND 2. One of the following: a. Currently on a prophylactic medication (beta-blocker, calcium channel blocker, antidepressant, anticonvulsant) OR b. Inadequate response, intolerance, or contraindication to all of the following migraine prophylactic drugs: divalproex, valproate, topiramate, amitriptyline, venlafaxine, atenolol, and nadolol, AND 3. Treatment failure or intolerable side effect with at least 2 different triptans, AND 4. Not taking D.H.E injection along with any triptan, or an ergot-type drug AND 5. The total number of injections requested per month does not exceed the amount needed to treat the number of headache days experienced per month Covered Doses Up to 3 mg per 24 hours, and up to 6 mg/week, IM or SQ Coverage Period Cover indefinitely ICD-10: G43.001- G43.819, G43.A01-G43.D19 (3) The following condition(s) DO NOT require Prior Authorization/Preservice All requests for D.H.E. 45® (dihydroergotamine mesylate injection) must be sent for clinical review and receive authorization prior to drug administration or claim payment. (4) This Medication is NOT medically necessary for the following condition(s) Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication. Please refer to the Provider Manual and User Guide for more information. (5) Additional Information How supplied: 1 mg/ml solution supplied in sterile ampules for I.V., I.M., or subcutaneous administration Table 1. AAN 2012 Classification of Migraine Preventative Therapies (Silberstein, 2012) Dihydroergotamine mesylate injection (D.H.E. 45®) Effective: 05/06/2020 Page 2 of 4 Level A Level B Level C Level U Other Established efficacy Probably effective Possibly effective Inadequate or Possibly or probably conflicting data to ineffective support or refute use Antiepileptics: Antidepressants: ACE Inhibitors: Antidepressants: Antiepileptics: • Divalproex sod • Amitriptyline • Lisinopril • Fluvoxamine • Lamotrigine • Valproate • Venlafaxine • Fluoxetine • Oxcarbazepine3 • Topiramate Alfa-agonists: Beta blockers: • Clonidine Antiepileptics: ARBs: Beta blockers: • Atenolol • Guanfacine • Gabapentin • Telmisartan • Metoprolol • Nadolol • Propranolol Antiepileptics: Antithrombotics: Beta blockers: • Timolol • Carbamazepine • Acenocoumarol • Acebutolol • Coumadin Antihistamines: Benzodiazepine: • Cyproheptadine Beta Blockers: • Clonazepam • Bisoprolol ARBs: NSAID: • Candesartan Ca Channel Blockers: • Nabumetone • Nicardipine Beta blockers: • Nifedipine TCA/Other: • Nebivolol • Nimodipine • Clomipramine • Pindolol • Verapamil Carbonic anhydrase inhibitor: • Acetazolamide Muscle relaxants: • Cyclandelate TCA: • Protriptyline ACE = ace inhibitor; ARB = angiotensin receptor blocker; TCA = tricyclic antidepressant (6) References • AHFS®. Available by subscription at http://www.lexi.com • Beithon J, Gallenberg M, Johnson K, et al. Diagnosis and Treatment of Headache. Institute for Clinical Systems Improvement. Updated January 2013. Available at: https://www.icsi.org/_asset/qwrznq/Headache.pdf • Dihydroergotamine mesylate injection [package insert], Novartis, distributed by Valeant Pharmaceuticals North America, revised 09/2009 • DrugDex®. Available by subscription at http://www.micromedexsolutions.com/home/dispatch • Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology. 2010; 75: 463-473. • Landy S, Smith. Treatment of primary headache: acute migraine treatment. In: Standards of care for headache diagnosis and treatment. Chicago (IL): National Headache Foundation; 2004, p.24-39. Available at: www.headaches.org • May A, Leone M, Afra J, et al. EFNS Task Force EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13:1066-1077 • Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: The American Headache Society evidence-based guidelines. Headache 2016; 56: 1093-1106. • Silberstein SD, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337- 1345. • Snow V, et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2000; 137:840-849. • Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013 Jul 15;88(2):122-8. Review. Dihydroergotamine mesylate injection (D.H.E. 45®) Effective: 05/06/2020 Page 3 of 4 (7) Policy Update Dates of last review: 2Q2020 Date of next review: 2Q2021 Changes from previous policy version: • No clinical change to policy following routine annual review. Dihydroergotamine mesylate injection (D.H.E. 45®) Effective: 05/06/2020 Page 4 of 4 .
Recommended publications
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Novel Formulations for Treatment of Migraine
    (19) TZZ _T (11) EP 2 756 756 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.07.2014 Bulletin 2014/30 A01N 43/42 (2006.01) A61K 31/44 (2006.01) (21) Application number: 14165112.5 (22) Date of filing: 24.04.2009 (84) Designated Contracting States: • Turanin, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Emeryville, CA California 94608 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Hawley, Roger PT RO SE SI SK TR Emeryville, CA California 94608 (US) • Schuster, Jeffrey, A. (30) Priority: 28.04.2008 US 48463 Bolinas, CA California 94924 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Duxbury, Stephen et al accordance with Art. 76 EPC: Arnold & Siedsma 09739139.5 / 2 273 880 Pettenkoferstrasse 37 80336 München (DE) (71) Applicant: Zogenix, Inc. Emeryville CA 94608 (US) Remarks: This application was filed on 17-04-2014 as a (72) Inventors: divisional application to the application mentioned • Farr, Stephen J. under INID code 62. Orinda, CA California 94563 (US) (54) Novel formulations for treatment of migraine (57) Systems and methods are described for treating Systems that are self contained, portable, prefilled, and un-met medical needs in migraine and related conditions simple to self administer at the onset of a migraine attack such as cluster headache. Included are treatments that are disclosed, and preferably include a needle-free in- are both rapid onset and long acting, which include sus- jector and a high viscosity formulation, to eliminate such tained release formulations, and combination products, issues as fear of self administration with needles, and Also included are treatments for multiple symptoms of needle stick and cross contamination.
    [Show full text]
  • Are You Eligible for the Senior Citizen Homeowner
    Please read but do not submit with your application Homeowner Tax Benefits Initial Application Instructions for Tax Year 2018/19 Please note: If the property has a life estate, only the individual retaining the life estate can apply. If the property is held in a trust, only the qualifying beneficiary/trustee can apply. Are you eligible for the Senior Citizen Homeowner Exemption (SCHE)? • Will all owners be 65 years of age or older by December 31, 2018? n Yes n No OR • If you own your property with either a spouse or sibling, will at least one of you be 65 years of age or older by December 31, 2018? • Will you have owned this property for at least 12 consecutive months prior n Yes n No to the date of filing this application? • Is the property the primary residence for ALL senior owners and their spouses? n Yes n No (All owners must reside on the property unless they are legally separated, divorced, abandoned or residing in a health care facility.*) *If an owner is residing in a health care facility, please submit documentation including total cost of care at the facility. • Is the Total Combined Income (TCI) for all owners and spouses $37,399 or less, n Yes n No regardless of where they live? (The income of a spouse may be excluded if he or she is absent from the residence due to divorce, legal separation or abandonment.) If you have answered NO to any of these questions, you MAY NOT be eligible for the Senior Citizen Homeowner Exemption.
    [Show full text]
  • Current and Prospective Pharmacological Targets in Relation to Antimigraine Action
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:371–394 DOI 10.1007/s00210-008-0322-7 REVIEW Current and prospective pharmacological targets in relation to antimigraine action Suneet Mehrotra & Saurabh Gupta & Kayi Y. Chan & Carlos M. Villalón & David Centurión & Pramod R. Saxena & Antoinette MaassenVanDenBrink Received: 8 January 2008 /Accepted: 6 June 2008 /Published online: 15 July 2008 # The Author(s) 2008 Abstract Migraine is a recurrent incapacitating neuro- (CGRP1 and CGRP2), adenosine (A1,A2,andA3), glutamate vascular disorder characterized by unilateral and throbbing (NMDA, AMPA, kainate, and metabotropic), dopamine, headaches associated with photophobia, phonophobia, endothelin, and female hormone (estrogen and progesterone) nausea, and vomiting. Current specific drugs used in the receptors. In addition, we have considered some other acute treatment of migraine interact with vascular receptors, targets, including gamma-aminobutyric acid, angiotensin, a fact that has raised concerns about their cardiovascular bradykinin, histamine, and ionotropic receptors, in relation to safety. In the past, α-adrenoceptor agonists (ergotamine, antimigraine therapy. Finally, the cardiovascular safety of dihydroergotamine, isometheptene) were used. The last two current and prospective antimigraine therapies is touched decades have witnessed the advent of 5-HT1B/1D receptor upon. agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute Keywords 5-HT. Antimigraine drugs . CGRP. treatment of migraine. Moreover, current prophylactic Noradrenaline . Migraine . Receptors treatments of migraine include 5-HT2 receptor antagonists, Ca2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its Introduction complex etiology, this disease still remains underdiagnosed, and available therapies are underused.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Contractile Responses to Ergotamine and Dihydroergotamine in The
    J Headache Pain (2007) 8:83-89 DOI 10.1007/s10194-007-0368-9 ORIGINAL Peer Tfelt-Hansen Contractile responses to ergotamine and Elisabeth Nilsson Lars Edvinsson dihydroergotamine in the perfused middle cerebral artery of rat Received: 2 November 2006 Abstract The vasomotor effects of 7.6±0.2 for ergotamine and Accepted in revised form: 22 January 2007 ergotamine and dihydroergotamine 8.4±0.5 for DHE. The responses Published online: 11 May 2007 (DHE) on the middle cerebral were blocked by the 5-HT2A recep- artery (MCA) of rats were studied tor antagonist ketanserin (concen- using the pressurised arteriography tration 10–12 to 10–5 M) and partial- method and in vitro myographs. ly with the 5-HT1B receptor antago- MCAs from Sprague–Dawley rats nist BRL-11557PM-B. The 5-HT1D were mounted on two glass receptor antagonist SB-224289-A micropipettes using the arterio- had no significant effect. Using a graph, pressurised to 85 mmHg myograph technique, isolated ring and luminally perfused. All vessels segments of the MCA with intact used attained spontaneous contrac- endothelium were mounted on two tile tone (34.9±1.8% of resting metal wires. Neither agonist P. Tfelt-Hansen tone) and responded to luminal caused relaxation of resting ves- Department of Neurology, adenosine triphosphate (ATP) with sels, however, they both responded Copenhagen University Hospital, dilatation (24.1±4.0%), which by weak contractile responses Glostrup, Denmark showed functioning endothelium. (26±3% of submaximal contractile E. Nilsson (౧) • L. Edvinsson Luminally added ergotamine or capacity relative to 60 mM potassi- Department of Internal Medicine, DHE induced maximal contrac- um).
    [Show full text]
  • Wednesday, February 10, 2016 4 P.M
    Wednesday, February 10, 2016 4 p.m. Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Bethany Holderread, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – February 10, 2016 DATE: February 1, 2016 Note: The DUR Board will meet at 4:00p.m. The meeting will be held at 4345 N Lincoln Blvd. Enclosed are the following items related to the February meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Oral Viscous Lidocaine Claims Analysis Update – Appendix B Action Item – Vote to Prior Authorize Duopa™ (Carbidopa/Levodopa Enteral Suspension) and Rytary™ (Carbidopa/Levodopa Extended-Release Capsules) – Appendix C Action Item – Vote to Prior Authorize Cortisporin® and Pediotic® (Neomycin/Polymyxin B/Hydrocortisone Otic) – Appendix D Action Item – Vote to Prior Authorize Migranal® (Dihydroergotamine Nasal Spray) – Appendix E Action Item – Vote to Prior Authorize Strensiq™ (Asfotase Alfa) – Appendix F Action Item – Vote to Prior Authorize Varubi™ (Rolapitant) – Appendix G Action Item – Vote to Prior Authorize Xuriden™ (Uridine Triacetate) – Appendix H Annual Review of Gout Medications and 30-Day Notice to Prior Authorize Mitigare™ (Colchicine Capsules) and Zurampic® (Lesinurad) – Appendix I Annual Review of Seizure Medications and 30-Day Notice to Prior Authorize Spritam® (Levetiracetam) – Appendix J 30-Day Notice to Prior Authorize Solaraze® (Diclofenac Gel) – Appendix K Annual Review of Ulcerative Colitis Medications and 30-Day Notice to Prior Authorize Uceris® (Budesonide Extended-Release Tablets), Uceris® (Budesonide Rectal Foam), and Miscellaneous Mesalamine Products – Appendix L Annual Review of Ocular Allergy Medications and 30-Day Notice to Prior Authorize Pazeo® (Olopatadine Ophthalmic) – Appendix M ORI-4403 • P.O.
    [Show full text]
  • Headache: Clinical Syndromes, Pathophysiology and Management
    HEADACHE: CLINICAL SYNDROMES, PATHOPHYSIOLOGY AND MANAGEMENT Joanna G Katzman, M.D., MSPH Assistant Professor UNM Pain Center and ECHO Pain University of New Mexico Health Sciences Center 11/14/13 After this session, participants will be able to identify and treat various non-migraine headache syndromes, including: Medication Overuse Cluster Tension Ominous (PTC, Meningitis. SAH) CLINICAL HEADACHE SYNDROMES 1. Migraine Headache 2. Cluster Headache 3. Tension-type Headache 4. Benign Intracranial Hypertension 5. Trigeminal Neuralgia 6. Cranial Arteritis 7. Subarachnoid Hemorrhage MIGRAINE PATHOPHYSIOLOGY Migraine Aura Spreading depression in the cortex Release of Potassium Release of glutamate The Trigeminovascular Theory Adapted from Lancet 1998;351:1045 MIGRAINE PATHOPHYSIOLOGY Pain Syndrome Trigeminal nucleus activated Calcitonin gene – related peptide (CGRP) released by trigeminal nerve CGRP release causes vasodilation Plasma protein extravasation causes sterile inflammation in the dura matter MIGRAINE HEADACHE COMMON 1. No aura 2. With nausea, vomiting, photophobia 3. Sleep alleviates symptoms 4. Familial history likely 5. Unilateral, throbbing quality of pain MIGRAINE HEADACHE CLASSICAL 1. With visual aura, such as scintillating scotoma or fortification spectra – thought to represent neuronal spreading depression within the occipital lobe 2. The remainder of clinical presentation is the same as with common migraine MIGRAINE HEADACHE COMPLICATED 1. Involves significant neurological deficits 2. Recovery may take hours to
    [Show full text]
  • Acute Reversible Cerebral Vasoconstriction Syndrome with Low-Dose Dihydroergotamine Possibly Potentiated by Valproic Acid and Erenumab: a Case Report
    Case Report J Neurol Res. 2020;10(1):20-24 Acute Reversible Cerebral Vasoconstriction Syndrome With Low-Dose Dihydroergotamine Possibly Potentiated by Valproic Acid and Erenumab: A Case Report Hsiangkuo Yuana, Stephanie J. Nahasa, Matthew A. Berka, b Abstract disabling headache attacks believed to be due to trigeminovas- cular dysfunction, can be challenging. Migraine preventives Dihydroergotamine (DHE), in the setting of polypharmacy, may increase carried over from medications designed for other medical con- the possibility of reversible cerebral vasoconstriction syndrome (RCVS). ditions (e.g., antiepileptics, antihypertensives, antidepressants) A 64-year-old woman with chronic migraine and medication-overuse commonly display unique adverse event (AE) profiles that headache (on amitriptyline, duloxetine, erenumab) was electively ad- can lead to reduced medication adherence and poor migraine mitted for 5 days of intravenous (IV) ketamine (up to 55 mg/h) to treat control [1]. In refractory migraine, use of intravenous (IV) intractable migraine pain. On the seventh day, upon receiving her forth medications such as lidocaine, dihydroergotamine (DHE), dose of IV DHE (0.25 mg) and the first of IV valproic acid (VPA) (500 or ketamine may offer acute relief [2, 3]. Despite achieving mg) adjunctively, she developed acute bilateral decreased visual acuity, greater headache control by using a cocktail of medications, bitemporal visual field deficit, and unsteady gait. Brain magnetic reso- unexpected AEs may occur, especially in the setting of poly- nance imaging/magnetic resonance angiography (MRI/MRA) showed pharmacy. Here, we report a case of a woman who developed confluent bilateral T2 hyperintensities with punctate restricted diffusion posterior reversible encephalopathy syndrome (PRES) and in the occipital lobes associated with multi-segmental narrowing involv- reversible cerebral vasoconstriction syndrome (RCVS) while ing anterior, middle, posterior cerebral, and basilar arteries consistent being treated with IV ketamine, neuroleptics, DHE, and other with RCVS.
    [Show full text]
  • Antiepileptic Drugs in Migraine Prophylaxis
    P1: KWW/KKL P2: KWW/HCN QC: KWW/FLX T1: KWW GRBT050-57 Olesen- 2057G GRBT050-Olesen-v6.cls July 25, 2005 16:28 ••Chapter 57 ◗ Antiepileptic Drugs in Migraine Prophylaxis Stephen D. Silberstein and Peer Tfelt-Hansen Migraine and epilepsy are both chronic, believed to result Therapeutic Use from brain hyperexcitability, and the therapeutic agents Carbamazepine (Tegretol), 600 to 1200 mg a day effective for each disorder overlap (1). These disorders are (beginning at 100 mg twice a day), is occasionally used, linked by their symptom profiles, comorbidity, and treat- particularly for patients who have coexisting mania or hy- ment (1,34,41). Each disorder provides a rationale for us- pomania, especially if there is rapid cycling. Monitor car- ing drugs that suppress neuronal excitability in migraine bamazepine plasma levels and white blood counts. prevention. Antiepileptic medication is recommended for migraine prevention because placebo-controlled, double-blind trials Clonazepam prove them effective (22,25,37,46,58). Despite the earlier Clonazepam was studied in one placebo-controlled belief that they are more effective in children who have crossover trial (58) of 34 patients. Those completing paroxysmal electroencephalograms (44), they are effective 4 weeks’ treatment (1 mg daily) had their mean headache regardless of the electroencephalogram (43). With the ex- days per month reduced by 50% compared with an 8% re- ception of valproic acid and topiramate, many anticon- duction for patients receiving placebo (p <0.05). The effect vulsants interfere with the efficacy of oral contraceptives was less at 2 mg daily. Drowsiness was a problem. (7,19). Gabapentin ANTIEPILEPTIC DRUGS Gabapentin’s mode of action in migraine is unclear (66).
    [Show full text]
  • 2. Letters and Sounds
    2. Letters and Sounds 2.1. Alphabet 2.1.1. The next table shows the relationship between the letters of the Greek alphabet and its derivatives, the Latin alphabet and the (newer) Cyrillic alphabet. GREEK LATIN CYRILLIC Α α Alpha A a А а Β β Beta B b Б б, В в Γ γ Gamma C c, G g Г г Δ δ Delta D d Д д Ε ε Epsilon E e Е е, Ё ё, Э э Ζ ζ Zeta Z z Ж ж, З з Η η (H)Eta H h И и, Й й Θ θ Theta Ι ι Iota I i, J j Κ κ Kappa K k К к Λ λ Lambda L l Μ μ Mu M m М м Ν ν Nu N n Н н Ξ ξ Xi Ο ο Omicron O o О о Π π Pi П п Ρ ρ Rho P p, R r Р р Σ σ ς Sigma S s С с Τ τ Tau T t Т т Υ υ Upsilon U u, Y y, W w У у Φ φ Phi Ф ф Χ χ Chi X x Х х Ψ ψ Psi Ω ω Omega F Digamma F f Q Qoppa Q q 55 Europaio: A Brief Grammar of the European Language 2.1.2. The Europaio Alphabet is similar to the English (which is in fact borrowed from the late Latin abecedarium), except that the C has a very different sound, similar to that of G. We also consider some digraphs part of the alphabet, as they represent original Europaio sounds, in contrast to those digraphs used mainly for transcriptions of loan words.
    [Show full text]